expected total cumulative dose received. Objective response rate (CR+PR) in the entire cohort was 66%. Median progression-free survival (PFS) from start of alternate schedule is 17.1 months (95% CI 5.2not reached). 6-month PFS is 65% (95% CI 46%-79%) starting from when alternate schedule of Nivo was begun. We will present updated toxicity and treatment outcomes in the meeting. Conclusion: Nivolumab 240mg administered at q 4 weeks or longer is feasible. Further investigation is needed to optimize patient selection for alternate dosing schedule.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.